Friday, October 12, 2012

Seeking Alpha: Lexicon Pushes On To Phase III

Lexicon Pharmaceuticals (LXRX) still isn't what I'd call a household name in biotech, even though the company has over $1 billion in market capitalization and at least two solid drug product candidates. With Friday's news of a successful Phase II study in carcinoid syndrome and the launch of a Phase III study, Lexicon investors have good reason for a little cheer going into the weekend.

Please continue here:
Lexicon Pushes On To Phase III

No comments: